Hospira Announces Voluntary Nationwide Recall of One Lot of 1% Lidocaine HCI INjection, USP, Due To Visible Particulates

Hospira, Inc. (NYSE: HSP), announced today it will initiate a voluntary recall of one lot of 1% Lidocaine HCI Injection, USP to the user level due to a confirmed customer report of orange and black particulate within the solution and embedded within the glass vial.

 
comments powered by Disqus